LipidShield - Capsules (60 ct)
 | | LipidShield is a revolutionary new product that has been scientifically designed to help safely control and maintain healthy cholesterol levels. Unlike many herbal supplements and pharmaceuticals that target one specific source, LipidShield targets the many causes of elevated cholesterol offering a more complete and effective alternative. This unique Doctor formulation also raises your HDL (good) cholesterol levels and lowers triglycerides making it one of the most heart healthy formulas available. LipidShield is a scientifically formulated, safe and effective natural alternative designed to help maintain cholesterol levels that are already in the normal range. This Doctor formulated product combines the power of plant phytosterols and plant stanols. The combination of these individual ingredients has been clinically tested for heart health and cholesterol reduction. This breakthrough product also includes policosanol and other natural herbal ingredients - Setting a New Standard! LipidShield is manufactured using cGMP standards in a FDA inspected and registered facility guaranteeing safety, effectiveness, and purity. | | | | | | Til informasjon:
| | | | | | Eventuelle produktspesifikasjoner:
About LipidShield
LipidShield- is a proprietary blend of several well known ingredients that have been known for their cholesterol reducing resulted in the following lipid improvements: LDL cholesterol reduced about 28%, total cholesterol about 20%, and HDL increased by 7-10%. Triglycerides were unaffected. During the course of the trial, participants continued on a low cholesterol diet. In other studies policosanol was shown to lower triglycerides as well as lowering total and LDL cholesterol and raising HDL cholesterol.
The diversity of beneficial effects from policosanol represents an effective alternative of natural source to lowering cholesterol for those seeking and in need of lipid-lowering resources who, are reluctant to use chemically derived drugs and would prefer a natural alternative.
References:
1. Aleman CL, Mas R, Hernandez C, et al. A 12 months study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett 1994;70: 77-87.
2. Arruzazabala M.L.; Molina V.; Mas R.; Fernández L.; Carbajal D.; Valdés S.; Castaño G. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients, Clinical and Experimental Pharmacology and Physiology, Volume 29, Number 10, October 2002, pp. 891-897(0).
3. Canetti MM, Moreira M, Mas R, et al. Effects of policosanol on primary hypercholesterolemia: a 3-year open extension follow-up. Curr Ther Res 1997;58:868-75.
4. Castaño G.; Mas R.; Fernández L.; Illnait J.; Mesa M.; Alvarez E.; Lezcay M. Comparison of the Efficacy and Tolerability of Policosanol with Atorvastatin in Elderly Patients with Type II Hypercholesterolaemia, Drugs & Aging, Volume 20, Number 2, 2003, pp. 153-163(11).
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
6. Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
7. Gonzales Canavaciolo VL, Magraner Hernandez J. Validation of a gas chromatographic method for determining fatty alcohols that compose policosanol in five-milligram film-coated tablets. J AOAC Int 1999;82:834-9.
8. Gonzales-Bravo D, Magraner-Hernandez J, Acosta-Gonzales PC, et al. Analytical procedure for the determination of 1-octacosanol in plasma by solvent extraction and capillary gas chromatography. J Chromatr 1996;682:359-63.
9. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91:2274-82.
10. Ichihara K, Kusunose E, Noda Y, et al. Some properties of the fatty alcohol oxidation system and reconstitution of microsomal oxidation activity in intestinal mucosa. Biochim Biophys Acta 1986;878: 412-8.
11. Ioanna Gouni-Berthold , MD ,a and Heiner K. Berthold, MD, PhDb, Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Rotenburg an der Fulda and Bonn, Germany. American Heart Journal, February 2002.
12. Jenkins AJ. Might money spent on statins be better spent? BMJ, Oct 2003; 327: 933-b.
13. Kabir Y, Kimura S. Biodistribution and metabolism of orally administered octacosanol in rats. Ann Nutr Metab 1993;37:33-8.
14. Kannel WB, Castelli WP, Gordon T, et al. Lipoprotein cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Heart Study. Ann Intern Med 1995;90:85-91.
15. Kawamura N, Moser HW, Kishimoto Y. Very long chain fatty acid oxidation in rat liver. Biochem Biophys Res Commun 1981;99: 1216-25.
16. Más R.; Castaño G.; Fernández L.; Illnait J.; Fernández J.; Alvarez E. Effects of Policosanol on Lipid Profile and Cardiac Events in Older Hypercholesterolaemic Patients with Coronary Disease, Clinical Drug Investigation, Volume 21, Number 7, 1 July 2001, pp. 485-497(13).
17. Menendez R, Amor AM, Gonzalez RM, et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996;29:253-7.
18. Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32.
19. Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27:199-203.
20. Menendez R, Sotolongo V, Fraga V, et al. Plasma levels and excretion of total radioactivity in healthy volunteers after oral administration of 3H-octacosanol. Rev CNIC Cien Biol 1996;27:32-5.
21. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP)—a multicenter survey to evaluate the percentages of low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459-67.
22. Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharm Res 1994; 14:27-33.
23. Rizzo WB, Craft DA, Dammann AL, et al. Fatty alcohol metabolism in cultured human fibroblasts: evidence for a fatty alcohol cycle. J Biol Chem 1987;262:17412-9.
24. Rodriguez MD, Garcia H. Evaluation of peri- and post-natal toxicity of policosanol in rats. Teratog Carcinog Mutagen 1998;18: 1-7.
25. Rodriguez MD, Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 1994;14:107-13.
26. Rodriguez MD, Sanchez M, Garcia H. Multigenerational reproduction study of policosanol in rats. Toxicol Lett 1997;90:97-106.
27. Sacks FM, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. New England Journal of Medicine, Oct 3, 1996; 335 (14): 1001-1009.
28. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994. 344; 1383-1389.
29. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269:3009-14.
30. Sever PS, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet, 2003 Apr 5;361(9364):1149-58.
31. Singh H, Derwas N, Poulos A. Very long chain fatty acid beta-oxidation by rat liver mitochondria and peroxisomes. Arch Biochem Biophys 1987;259:382-90.
32. The Long-Term Intervention with Pravastatin In ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 1998. Vol. 339: 1349-1357.
33. Zardoya R, Tula L, Castano G, et al. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function. Curr Ther Res 1996;57:568-77.
Guggul
This natural ingredient is derived from the mixture of plant chemicals (ketonic steroids) from the gum resin of Commiphora mukul, called guggulipid, and is an approved treatment of hyperlipidemia in India. It has been a mainstay of traditional Indian herbal medicine (Ayurveda) approaches in preventing high cholesterol and atherosclerosis. Clinical studies indicate it to be effective in the treatment of elevated cholesterol, elevated triglyceride levels and elevated LDL (bad cholesterol) levels. Studies have also shown that LDL oxidation, which is the main cause of plaque build in the arteries, can be prevented or at least decreased by the antioxidant activity of Guggul. Clinical studies on Guggul indicate that its hypolipidemic activity (decreasing cholesterol and other lipids) can be attributed to more than one mechanism. Three of the possible mechanisms include inhibition of cholesterol biosynthesis, enhancing the rate of excretion of cholesterol and promoting rapid degradation of cholesterol. Guggul is typically manufactured in a standardized form that provides a fixed amount of guggulipid, the presumed active ingredients in Guggul. Guggul helps reduce high cholesterol, because it lowers harmful LDL (low-density lipoproteins) while elevating the beneficial HDL (high-density lipoproteins). Guggul also has anti-inflammatory activity and reduces the levels of C-reactive protein. It helps prevent blood platelet aggregation and breaks up blood clots. Thus Guggul can be used not only to lower bad cholesterol but can be used as a preventative against heart disease and stroke.
References:
1. Atherosclerosis. 2004 Feb;172(2):239-46 The hypolipidemic natural product Commiphora mukul and its component guggulsterone inhibit oxidative modification of LDL.
2. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with guggulipid. A new hypolipidaemic agent. J Assoc Phys India 1989;37:323-8.
3. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994;8:659-64.
4. Urizar NL, Moore DD. Guggulipid: a natural cholesterol-lowering agent Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. nurizar@bcm.tmc.edu
5. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003;290(6):765-772.
Red yeast rice
Red Yeast Rice has been used in China for centuries as both a food and as a medicinal substance. It is made by fermenting a type of yeast called Monascus purpureus over red rice. In Chinese medicine, red yeast rice is used to promote blood circulation, soothe upset stomach, and invigorate the function of the spleen, a body organ that destroys old blood cells and filters foreign substances. In addition, this dietary supplement has been used traditionally for bruised muscles, hangovers, indigestion, and colic in infants.
In a study conducted at UCLA School of Medicine, by David Heber, 83 people with high cholesterol levels received red yeast rice over a 12-week period. The study concluded that red yeast rice significantly reduces total cholesterol, LDL cholesterol, and total triacylglycerol concentrations when compared to those who received placebo.
In a study involving 187 patients with elevated cholesterol were treated with red yeast rice daily for eight weeks. At the end of this eight-week trial, total cholesterol decreased by 16%, LDL by 21%, triglycerides by 24%. HDL cholesterol also increased by 14%.
In another 8-week trial involving a 324 people with high cholesterol levels, those who received red yeast rice experienced a significant drop in cholesterol levels compared to those who received placebo. Total cholesterol fell by 22.7%, LDL by 31%, and triglycerides by 34% in the red yeast rice group. HDL cholesterol increased by 20% in the red yeast rice group as well.
1. Altern Med Rev. 2004 Jun;9(2):208-210. The medicinal properties of red yeast rice favorably impact lipid profiles of hypercholesterolemic patients.
2. American Journal of Clinical Nutrition, Vol. 69, No. 2, 231-236, February 1999. Center for Human Nutrition, Department of Medicine, UCLA School of Medicine, Los Angeles, CA: David Heber, Ian Yip, Judith M Ashley, David A Elashoff, Robert M Elashoff and Vay Liang W Go. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement.
3. Nutr Res 18, 71-81 (1998). Li, C et al. (1998). Monascus purpureus-fermented rice (red yeast rice): A natural food product that lowers blood cholesterol in animal models of hypercholesterolemia.
4. American Heart Association. 39 th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, Orlando, Fl. March 1999. Bonovich, K, Colfer H, Davidson M, Dujovne C, Greenspan M, Karlberg R, et al. A Multi-Center, Self-Controlled Study of Cholestin In Subjects With Elevated Cholesterol.
5. Cur Ther Res. 1997;58:964-978. Wang J, Lu Z, Chi, et.al.; A multi-center clinical trial of the serum lipid-lowering effect of Monascus purpureus (red yeast) rice preparation from TCM.
Selenomethionine
Selenium—prevents ventricular tachycardia, is a hypolipidemic, and improves diabetic symptoms, congestive heart failure, and cardiomyopathy.
Cardiomyopathy is defined as any disease that affects the structure and function of the heart. For example, the heart may become disabled as fibrous tissue partially replaces the heart muscle; the fibrous tissue degrades the heart's performance and the blood no longer moves efficiently. The World Health Organization recognizes cardiomyopathy as a selenium deficiency. In addition, French researchers showed that chronic heart failure (associated with oxidative stress) appears to be relieved by selenium supplementation.
Inositol Hexanicotinate
Flush-free niacin may lower cholesterol while boosting the beneficial HDL fraction. In a report on the antiatherogenic role of HDL (high density lipoprotein) cholesterol, flush-free niacin (inositol hexanicotinate) "appears to have the greatest potential to increase HDL cholesterol by 30%." This study was made over a 5-year period and focused on the effect of high LDL numbers exhibited before a patient's first coronary event(s).
As reported in a November 1998 American Journal of Cardiology research study, "Nicotinic acid (niacin) has been shown to decrease triglyceride, increase HDL cholesterol, lower LDL cholesterol, and decrease lipoprotein (a); it also decreases fibrinogen," an additional benefit that reduces the risk of related cardiovascular disease. | | | | Se også mine andre auksjoner: Se selgers auksjoner |
|
![[Header_SearchHelp]](/ImgWeb/20//V3/header/question.gif)
